A Phase Ib Clinical Trial to Assess the Safety and Immunogenicity of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/Matrix-M in Healthy Adults and Infants in Tanzania
Latest Information Update: 26 Nov 2024
Price :
$35 *
At a glance
- Drugs RH 5.1 (Primary)
- Indications Falciparum malaria
- Focus Adverse reactions
- 22 Nov 2024 Status changed from active, no longer recruiting to completed.
- 21 Jul 2023 Status changed from recruiting to active, no longer recruiting.
- 29 Jul 2021 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT04318002)